1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsOngoing trial evaluating the efficacy of muvalaplin, a small molecule inhibitor, in reducing cardiovascular events among individuals with elevated lipoprotein(a) levels.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Clinical research organizations, academic institutions, and healthcare providers involved in cardiovascular research. Confirm the full requirements in the official notice before applying.
MOVE-Lp(a) Trial is funded by Novartis. Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Patient Education Grants is sponsored by Novartis. Novartis provides financial support for educational, advocacy, and outreach activities that improve patient and public health. They accept patient education grant requests from 501(c)(3), 501(c)(4), or 501(c)(6) nonprofit organizations for activities like disease awareness, live events, web-based education, and newsletters in various therapeutic areas, including rare diseases.
Professional Medical Education Grants is sponsored by Novartis. Novartis provides grants to US organizations to support high-quality educational programs for US Healthcare Professionals (HCPs) and patient education initiatives in the US. They evaluate professional medical education grant requests that are independent of commercial bias and non-promotional. This can include live events, web-based education, and enduring materials. Novartis also evaluates grant requests in support of research fellowships and awards from academic medical centers, medical universities, and professional medical associations/societies.